Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (отвара нови прозор)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Извор‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Индекс‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (отвара нови прозор)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (отвара нови прозор)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Извор‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Индекс‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (отвара нови прозор)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (отвара нови прозор)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Извор‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Индекс‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (отвара нови прозор)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (отвара нови прозор)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Извор‎: Blood 2003;102(4):1529-30.

Индекс‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (отвара нови прозор)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (отвара нови прозор)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Извор‎: Transfusion 2007;47(10):1830-6.

Индекс‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (отвара нови прозор)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (отвара нови прозор)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Извор‎: Iran J Blood Cancer 2009;1(4):147-50.

Индекс‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (отвара нови прозор)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (отвара нови прозор)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Извор‎: Int J Hematol 2012;95(1):51-6.

Индекс‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (отвара нови прозор)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (отвара нови прозор)

Perrine SP.

Извор‎: Pediatr Ann 2008;37(5):339-46.

Индекс‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (отвара нови прозор)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (отвара нови прозор)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Извор‎: Sci Rep. 2022;12(1):2752.

Индекс‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (отвара нови прозор)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (отвара нови прозор)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Извор‎: Haematologica 2004;89(10):1172-8.

Индекс‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (отвара нови прозор)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (отвара нови прозор)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Извор‎: Arch Iran Med 2009;12(3):295-7.

Индекс‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (отвара нови прозор)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (отвара нови прозор)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Извор‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Индекс‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (отвара нови прозор)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (отвара нови прозор)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Извор‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Индекс‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (отвара нови прозор)

Fetal globin gene inducers: novel agents and new potential. (отвара нови прозор)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Извор‎: Ann N Y Acad Sci 2010;1202:158-64.

Индекс‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (отвара нови прозор)